Correction: The Economics of Reproducibility in Preclinical Research
Open accessAbstract
[This corrects the article DOI: 10.1371/journal.pbio.1002165.].
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The economic impact of irreproducible research, of which cell-line problems constitute a major share, has been estimated at $28 billion per year in the United States alone.
“The financial fallout is vast with irreproducible research linked to faulty cell stocks costing the United States an estimated $28 billion each year.”
From Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review (2026) · cites this paper as [15]
36.1% of the cost of contaminated or misidentified cell usage is believed to be linked to biological reagents and reference materials.
“the usage of contaminated or misidentified cells could cost the US over $28 billion/year from which 36.1% are believed to be linked to biological reagents and reference materials [15,140].”
From Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review (2026) · cites this paper as [15]
The usage of contaminated or misidentified cells could cost the US over $28 billion per year.
“the usage of contaminated or misidentified cells could cost the US over $28 billion/year from which 36.1% are believed to be linked to biological reagents and reference materials [15,140].”
From Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review (2026) · cites this paper as [15]
A meaningful STR test including the electrophoretic profile typically costs around $100-200, while consumable costs are about $40 for baseline STR genotyping.
“currently, companies provide a meaningful STR test, including the electrophoretic profile, typically costing around $100–200, while the consumable costs are about $40 for base line STR genotyping [15,138,139].”
From Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review (2026) · cites this paper as [15]
Cites
The economics of reproducibility in preclinical research
Freedman, L. P., Cockburn, I. M., & Simcoe, T. S. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002165 · Cited by 1,055 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review
Weiskirchen, R. (2026) · Medical Sciences · doi:10.3390/medsci14010025 · Cited by 4 · see citing works
- Authors
- Staff, T. P. B.
- Corresponding author
- The PLOS Biology Staff
- Venue
- PLOS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-04-10
- Volume
- 16
- Issue
- 4
- Pages
- e1002626
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC5892864
- OpenAlex
- W4248790932
- Cited by
- 7
- References
- 1
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Biology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Social Sciences › Decision Sciences › Information Systems and Management › Academic Publishing and Open Access
- Social Sciences › Decision Sciences › Information Systems and Management › Research, Science, and Academia
- Keywords
- reproducibility, preclinical research, research economics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
